September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for HER2+ Metastatic NSCLC
August 12th 2022Accelerated approval has been granted to trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic non-small cell lung cancer based on positive results from DESTINY-Lung02.
Read More
Upfront Avelumab Shows Modest Survival Benefit Over Chemo in Advanced PD-L1+ NSCLC
August 9th 2022Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.
Read More
Pembrolizumab Plus Etoposide Continues to Show Survival Benefit in Untreated ES-SCLC
August 9th 2022Pembrolizumab and etoposide continues to demonstrate improvements in survival outcomes compared with placebo and etoposide in patients with previously untreated extensive stage-small cell lung cancer.
Read More
New Strategies Needed for Patients With NSCLC Who Progress on Chemoimmunotherapy
August 8th 2022Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.
Read More
Neoadjuvant Chemoimmunotherapy Shows Significant Survival Benefit in Stage III NSCLC
August 8th 2022Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.
Read More
Pembrolizumab/Lenvatinib Combo Shows Positive Clinical Activity in Recurrent Pleural Mesothelioma
August 7th 2022Pembrolizumab plus lenvatinib demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma, according to results from the PEMMELA study.
Read More
Use of Neoadjuvant Chemoimmunotherapy Supported in Stage IIIA NSCLC
August 7th 2022Using neoadjuvant chemoimmunotherapy to treat patients with stage IIIA resectable non–small cell lung cancer based on differences between pathologic complete responders and non–pathologic complete responders is supported by the phase 2 NADIM trial.
Read More
Neoadjuvant Adagrasib With or Without Nivolumab May Better pCR Rates in NSCLC
August 6th 2022The phase 2 Neo-KAN study revealed neoadjuvant adagrasib alone or in combination with nivolumab may improve pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer.
Read More
Where Will Tumor-Infiltrating Lymphocyte (TIL) Therapy Fit Into the Oncologic Landscape?
August 5th 2022In the first installment of the series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale behind tumor-infiltrating lymphocytes and considers where these experimental therapies may fit in the oncologic landscape.
Watch
Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC
August 3rd 2022During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.
Read More
Subcutaneous Atezolizumab Non-Inferior to IV Formulation in Locally Advanced or Metastatic NSCLC
August 2nd 2022In the phase 3 IMscin001 clinical trial, the use of subcutaneous atezolizumab demonstrated similar efficacy, safety, and pharmacokinetics compared with intravenous atezolizumab in patients with immunotherapy-naïve locally advanced or metastatic non—small cell lung cancer.
Read More
Clinical Commentary: How Immunotherapy Is Used for Treatment of Patients with ES-SCLC and NSCLC
July 27th 2022At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.
Read More